Corcept Therapeutics (CORT) crashed on Dec. 31 after the Food and Drug Administration (FDA) rejected its application for relacorilant, its investigational treatment for Cushing’s syndrome.
The agency’s Complete Response Letter cited insufficient data for conducting a favorable benefit-risk assessment, requiring additional evidence of effectiveness for the hypertension treatment in patients with hypercortisolism.
